• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名68岁的哥伦比亚男性,患有心力衰竭,被诊断为心脏转甲状腺素蛋白淀粉样变性。

A 68-Year-Old Colombian Man Presenting with Heart Failure and a Diagnosis of Cardiac Transthyretin Amyloidosis.

作者信息

Uribe-Buritica Francisco L, Cárdenas-Marín Paula Andrea, López-Ponce de León Juan David

机构信息

Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cali, Colombia.

Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.

出版信息

Am J Case Rep. 2024 Dec 9;25:e943811. doi: 10.12659/AJCR.943811.

DOI:10.12659/AJCR.943811
PMID:39652516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11642121/
Abstract

BACKGROUND Amyloidosis is a group of diseases characterized by the pathological deposition of misfolded proteins in various organs, including the heart, leading to structural and functional alterations. The primary types of cardiac amyloidosis are light chain amyloidosis and transthyretin amyloidosis. Early diagnosis is critical for effective management. This report describes the case of a 68-year-old Colombian man presenting with heart failure and a diagnosis of cardiac amyloidosis. CASE REPORT A 68-year-old man presented with heart failure symptoms, biceps tendon rupture, neuropathic pain in the extremities, and an electrocardiogram showing low QRS voltage and a pseudo-infarct pattern. Transthoracic echocardiogram revealed a left ventricular ejection fraction of 30%, severely thickened walls with a speckled appearance, a global longitudinal strain of -6.2% in a bull's eye pattern, and a left ventricular posterior wall thickness of 21.3 mm. Cardiac magnetic resonance imaging showed severe symmetric hypertrophy, moderate global dysfunction, and an elevated native T1 value of 1225 milliseconds. Post-gadolinium T1 mapping revealed a significantly increased extracellular volume of 72%. Perugini grade 3 pyrophosphate scintigraphy, negative hematological tests, and endomyocardial biopsy confirmed the diagnosis of amyloidosis, without monoclonal spikes. Genetic testing identified a heterozygous c.424G>A (p.Val142Ile) variant in the transthyretin gene, consistent with variant transthyretin amyloidosis. CONCLUSIONS Amyloidosis may affect up to 13% of patients with heart failure and preserved ejection fraction. Early recognition of red flags and implementation of a diagnostic algorithm are crucial for timely intervention in this population.

摘要

背景

淀粉样变性是一组以错误折叠的蛋白质在包括心脏在内的各种器官中病理性沉积为特征的疾病,可导致结构和功能改变。心脏淀粉样变性的主要类型是轻链淀粉样变性和转甲状腺素蛋白淀粉样变性。早期诊断对于有效治疗至关重要。本报告描述了一名68岁哥伦比亚男性患者,其表现为心力衰竭并被诊断为心脏淀粉样变性。病例报告:一名68岁男性出现心力衰竭症状、肱二头肌肌腱断裂、四肢神经性疼痛,心电图显示QRS波低电压和假性梗死图形。经胸超声心动图显示左心室射血分数为30%,室壁严重增厚且呈斑点状外观,整体纵向应变呈靶心样为-6.2%,左心室后壁厚度为21.3毫米。心脏磁共振成像显示严重的对称性肥厚、中度整体功能障碍,固有T1值升高至1225毫秒。钆增强后T1映射显示细胞外容积显著增加至72%。佩鲁吉尼3级焦磷酸盐闪烁扫描、血液学检查阴性以及心内膜活检确诊为淀粉样变性,无单克隆峰。基因检测在转甲状腺素蛋白基因中鉴定出一个杂合的c.424G>A(p.Val142Ile)变异,符合变异型转甲状腺素蛋白淀粉样变性。结论:淀粉样变性可能影响高达13%的射血分数保留的心力衰竭患者。早期识别警示信号并实施诊断算法对于该人群的及时干预至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/d4cdf120ab9d/amjcaserep-25-e943811-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/8ff324d27235/amjcaserep-25-e943811-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/b9646f8ea0d0/amjcaserep-25-e943811-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/36da6cf4a998/amjcaserep-25-e943811-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/254d2d1758d0/amjcaserep-25-e943811-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/b6cdd6e4f806/amjcaserep-25-e943811-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/5a83e51b33bb/amjcaserep-25-e943811-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/d4cdf120ab9d/amjcaserep-25-e943811-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/8ff324d27235/amjcaserep-25-e943811-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/b9646f8ea0d0/amjcaserep-25-e943811-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/36da6cf4a998/amjcaserep-25-e943811-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/254d2d1758d0/amjcaserep-25-e943811-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/b6cdd6e4f806/amjcaserep-25-e943811-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/5a83e51b33bb/amjcaserep-25-e943811-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf87/11642121/d4cdf120ab9d/amjcaserep-25-e943811-g007.jpg

相似文献

1
A 68-Year-Old Colombian Man Presenting with Heart Failure and a Diagnosis of Cardiac Transthyretin Amyloidosis.一名68岁的哥伦比亚男性,患有心力衰竭,被诊断为心脏转甲状腺素蛋白淀粉样变性。
Am J Case Rep. 2024 Dec 9;25:e943811. doi: 10.12659/AJCR.943811.
2
First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.沙特阿拉伯心脏淀粉样变性临床特征与转归的首次报告。
ESC Heart Fail. 2024 Dec;11(6):4348-4359. doi: 10.1002/ehf2.15045. Epub 2024 Sep 1.
3
Cardiac amyloidosis: updates in diagnosis and management.心脏淀粉样变性:诊断与治疗进展。
Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23.
4
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.与Pro24Ser转甲状腺素蛋白突变相关的遗传性心脏淀粉样变性:一例报告
J Med Case Rep. 2018 Dec 16;12(1):370. doi: 10.1186/s13256-018-1931-5.
5
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.野生型转甲状腺素蛋白心脏淀粉样变在老年人群中并不罕见:CATCH 筛查研究。
Eur J Prev Cardiol. 2024 Aug 22;31(11):1410-1417. doi: 10.1093/eurjpc/zwae093.
6
Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.65岁以上射血分数保留的心力衰竭患者左心室成像表型的初步研究:淀粉样心肌病的高患病率
Int J Cardiovasc Imaging. 2016 Sep;32(9):1403-1413. doi: 10.1007/s10554-016-0915-z. Epub 2016 May 30.
7
Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.心肌ATTR 淀粉样变的诊断和治疗进展。
Heart Fail Rev. 2019 Jul;24(4):521-533. doi: 10.1007/s10741-019-09776-3.
8
Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction.射血分数保留的未分化心力衰竭中甲状腺转运蛋白心脏淀粉样变的患病率。
ESC Heart Fail. 2025 Apr;12(2):1176-1182. doi: 10.1002/ehf2.15112. Epub 2024 Nov 7.
9
Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.锝焦磷酸盐闪烁扫描术:转甲状腺素淀粉样变心肌病早期诊断的实用指南。
ESC Heart Fail. 2022 Feb;9(1):251-262. doi: 10.1002/ehf2.13693. Epub 2021 Nov 29.
10
Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变性诊断与管理的实用建议。
Heart Fail Rev. 2021 Jul;26(4):861-879. doi: 10.1007/s10741-020-10062-w. Epub 2021 Jan 15.

本文引用的文献

1
Heart of the Matter: Decoding the Underdiagnosed Cardiac Amyloidosis.问题的核心:解读未被充分诊断的心脏淀粉样变性
Cureus. 2023 Dec 14;15(12):e50527. doi: 10.7759/cureus.50527. eCollection 2023 Dec.
2
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.2023年美国心脏病学会关于心脏淀粉样变性患者综合多学科护理的专家共识决策路径:美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. doi: 10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23.
3
Transthyretin cardiac amyloidosis.
转甲状腺素蛋白心脏淀粉样变性。
Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. doi: 10.1093/cvr/cvac119.
4
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey.揭示现实世界中淀粉样变性心肌病的流行情况:来自 AC-TIVE 研究第二阶段的结果,这是一项意大利全国性调查。
Eur J Heart Fail. 2022 Aug;24(8):1377-1386. doi: 10.1002/ejhf.2504. Epub 2022 May 10.
5
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.转甲状腺素蛋白淀粉样变预后调查中野生型转甲状腺素蛋白淀粉样心肌病的时间趋势
JACC CardioOncol. 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jaccao.2021.08.009. eCollection 2021 Oct.
6
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗:欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
7
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.系统性淀粉样变的识别、预后和治疗:系统评价。
JAMA. 2020 Jul 7;324(1):79-89. doi: 10.1001/jama.2020.5493.
8
The Pathology of Amyloidosis in Classification: A Review.淀粉样变的病理学分类:综述。
Acta Haematol. 2020;143(4):322-334. doi: 10.1159/000506696. Epub 2020 May 11.
9
Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.转甲状腺素蛋白心脏淀粉样变:诊断与治疗的最新进展。
ESC Heart Fail. 2019 Dec;6(6):1128-1139. doi: 10.1002/ehf2.12518. Epub 2019 Sep 25.
10
Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.转甲状腺素蛋白心脏淀粉样变的诊断与治疗。进展与希望。
Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):991-1004. doi: 10.1016/j.rec.2017.05.036. Epub 2017 Sep 1.